Cost-effectiveness of pembrolizumab for the adjuvant...

  • Main
  • 2019 / 04
  • Cost-effectiveness of pembrolizumab for the adjuvant...
Journal of Medical Economics 2019 / 04

Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States

Bensimon, Arielle G., Zhou, Zheng-Yi, Jenkins, Madeline, Song, Yan, Gao, Wei, Signorovitch, James, Krepler, Clemens, Liu, Frank Xiaoqing, Wang, Jingshu, Aguiar-Ibáñez, Raquel
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Journal:
Journal of Medical Economics
DOI:
10.1080/13696998.2019.1609485
Date:
April, 2019
File:
PDF, 1.02 MB
2019
Conversion to is in progress
Conversion to is failed